ASH 2017 | Exciting results for frontline ibrutinib plus FCR for younger CLL patients
There are now many effective therapies to choose from for chronic lymphocytic leukemia (CLL). Thus, a recent area of therapeutic development in CLL is the creation of time-limited regimens and curative treatment plans. In this interview, Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Phase II study of ibrutinib plus FCR as a frontline therapy for CLL patients (NCT02251548), with the exciting aim of improving cure rates in low- and high-risk patients. Dr Davids provides an overview of the impressive results regarding response rate, response depth and MRD negativity. He also highlights exciting future plans for the study, in patients who become MRD negative. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
